Data as of Q4 2025 (Dec 31, 2025)

REVOLUTION MEDICINES, INC.

(RVMD)

Financial Statements · SEC EDGAR XBRL

Revenue
$0
Net Income
-$1.13B
-88.5%
EPS
$-5.95
-66.2%
Op. Income
-$1.18B
-71.5%
FCF
-$913.7M
-60.9%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$0
$0
$11.6M
$35.4M
$29.4M
$0
$0
$11.6M
$35.4M
$29.4M
$987.3M
$592.2M
$423.1M
$253.1M
$186.9M
$1.18B
$689.5M
$498.8M
$293.7M
$217.4M
-$1.18B
-$689.5M
-$487.2M
-$258.3M
-$188.0M
-
-
-
$0
$12K
$51.1M
$88.7M
$47.3M
$9.2M
$917K
-$1.13B
-$600.8M
-$439.9M
-$249.1M
-$187.1M
$0
-$753K
-$3.5M
-$420K
$0
-$1.13B
-$600.0M
-$436.0M
-$249.0M
-$187.0M
$-5.95
$-3.58
$-3.86
$-3.08
$-2.57
$-5.95
$-3.58
$-3.86
$-3.08
$-2.57
190.1M
167.7M
113.1M
80.6M
72.8M